Adagene Inc. (ADAG): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADAG Stock Price Chart Interactive Chart >
ADAG Price/Volume Stats
| Current price | $1.50 | 52-week high | $4.46 |
| Prev. close | $1.52 | 52-week low | $0.90 |
| Day low | $1.50 | Volume | 1,700 |
| Day high | $1.55 | Avg. volume | 25,289 |
| 50-day MA | $1.74 | Dividend yield | N/A |
| 200-day MA | $1.53 | Market Cap | 64.88M |
Adagene Inc. (ADAG) Company Bio
Adagene Inc. operates as a biotechnology company. The Company focuses on the development of antibodies to cancer patients. Adagene serves patients in the United States and China.
Latest ADAG News From Around the Web
Below are the latest news stories about ADAGENE INC that investors may wish to consider to help them evaluate ADAG as an investment opportunity.
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April- Clinical posters detail results of dose escalation portion of phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, demonstrating benefits of SAFEbody precision masking technology - - Additional poster reports preclinical profile for ADG153, a novel masked anti-CD47 IgG1 SAFEbody demonstrating strong in vivo anti-tumor activities in solid tumor models and preferential CD47 target engagement in the tumor microenvironment - SAN DIEGO and SUZHOU, China, March 14, 2023 (GLOBE NEWSWI |
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board- Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities - - Expertise contributes to Adagene’s novel anti-CTLA-4 therapies delivered systemically at higher and repeated doses with compelling safety - SAN DIEGO and SUZHOU, China, March 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appoi |
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology - - Partial responses confirmed in multiple tumor types and continuous tumor shrinkage in cold tumors (e.g., MSS CRC) and anti-PD-1-resistant patients - - Dose expansion in combination with anti-PD-1 therapy ongoing at different dosing regimens - SAN DIEGO and SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. |
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update at the Biotech Showcase™ 2023, taking place January 9-11th in San Francisco, in parallel to the annual J.P. Morgan Healthcare Conference. Details of the event are as follows: Date:Mon |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Thursday! |
ADAG Price Returns
| 1-mo | -13.79% |
| 3-mo | 29.31% |
| 6-mo | 13.64% |
| 1-year | -65.28% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 13.21% |
| 2022 | -83.58% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...